Research and Markets: World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/hjq24x/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Aduro BioTech, Inc.
  • Advantagene, Inc.
  • Amphera BV
  • AnGes MG, Inc.
  • ArQule, Inc.
  • Bayer AG
  • Biogen, Inc.
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • CanBas Co., Ltd.
  • Concordia Healthcare Corp.
  • EnGeneIC Ltd
  • F. Hoffmann-La Roche Ltd.
  • Five Prime Therapeutics, Inc.
  • Genelux Corporation
  • GlaxoSmithKline Plc
  • Juno Therapeutics Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • MolMed S.p.A.
  • Morphotek, Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Oxford BioMedica Plc
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Polaris Pharmaceuticals, Inc.
  • Synta Pharmaceuticals Corp.
  • Verastem, Inc.
  • Virttu Biologics Limited

Drug Profiles

  • Ad5-SGE-REIC/Dkk3
  • amatuximab
  • anetumab ravtansine
  • ascrinvacumab
  • bevacizumab
  • BG-00001
  • BMS-986148
  • BNC-105
  • CBP-501
  • Cell Therapy 1 for Oncology
  • Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia
  • CRS-207
  • FP-1039
  • ganetespib
  • GEN-0101
  • Gene Therapy for Malignant Pleural Mesothelioma
  • Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma
  • GLONC-1
  • GSK-2256098
  • HSV-1716
  • iCasp9M28z
  • JTCR-016
  • MesoCancerVac
  • MesoCART
  • Monoclonal Antibody Conjugated to Target Mesothelin for Oncology
  • napabucasin
  • NGR-hTNF
  • nintedanib
  • nivolumab
  • pegargiminase
  • pembrolizumab
  • porfimer sodium
  • rAd-IFN
  • Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer
  • TargomiRs

For more information visit http://www.researchandmarkets.com/research/hjq24x/malignant_pleural

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology